OOIR: Observatory of International Research

Papers

(The median citation count of Lancet Infectious Diseases is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Transaminases and serum albumin as early predictors of severe dengue – Authors' reply	1609
Environment and infectious diseases	1207
A step forward in the journey towards hookworm vaccines	890
Listeria monocytogenes: a rare, deadly cause of peritonitis	796
Surge of cutaneous leishmaniasis in Pakistan	674
Updated criteria for paediatric sepsis and septic shock	655
Is ceftriaxone similarly effective to benzylpenicillin in neurosyphilis? – Authors' reply	592
Research in brief	591
Towards a marketplace for Vi polysaccharide-conjugate typhoid vaccines	476
Research in brief	451
Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting	436
Role of the G20 in safe reopening of international travel	395
Oral treatment of Whipple's disease with doxycycline and hydroxychloroquine versus intravenous therapy with ceftriaxone followed by oral trimethoprim–sulfamethoxazole in Germany: a phase 2/3, prospect	366
Attention to skin-related neglected tropical diseases	366
Infectious disease surveillance update	354
Chronicling PEPFAR's work in Africa	345
Ordinary people in extraordinary times	321
Infectious disease surveillance update	312
Rajendra Kapila	303
Promoting diversity and equity in publishing	275
Entering a labyrinth of COVID-19 stories	270
Correction to Lancet Infect Dis 2024; published online April 3. https://doi.org/10.1016/S1473-3099(24)00142-7	266
SARS-CoV-2 incidence and vaccine escape	263
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges	261
Adaora “Ada” Alise Adimora	254

The next chapter for Africa's genomic initiatives	253
The superiority of bivalent over monovalent booster vaccines	251
Malaria outbreak in Laos caused by formerly rare artemisinin resistant strains of Plasmodium falciparum	243
DNDi receives Dutch funding boost	239
COVID-19 vaccination protects children and adolescents	237
Can the USA return to pre-COVID-19 normal by July 4?	233
Circulation of avian Chlamydia abortus in the Netherlands and community-acquired pneumonia: an outbreak investigation and retrospective cohort study	232
Reflecting on lessons from the 2014–16 Ebola virus outbreak	215
The interplay between COVID-19 restrictions and vaccination	213
A bedaquiline, pretomanid, moxifloxacin, and pyrazinamide regimen for drug-susceptible and drug-resistant tuberculosis	208
Bold measures to accelerate malaria elimination	205
A patient with secondary syphilis following incomplete treatment of primary infection	203
Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study	203
Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis	202
Transitioning to endemicity with COVID-19 research	199
Neuropathology, pathomechanism, and transmission in zoonotic Borna disease virus 1 infection: a systematic review	198
Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic	198
Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial	194
Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial	190
HIV vaccine trial failure	185
Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations	185
Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1	174
Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation	169
Chikungunya vaccine VLA1553 induces sustained protective antibody concentrations	164
Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial	161
Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged ≥18 years: a randomised, double-blind, phase 2b tria	160
Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial	159
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study	158
Effectiveness of ceftazidime–avibactam versus ceftolozane–tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study	157
Threat of HIV and tuberculosis drug resistance after US funding cuts	155
Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden	153
Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-inco	153
Efficacy and safety of co-administered ivermectin and albendazole in school-aged children and adults infected with Trichuris trichiura in Côte d'Ivoire, Laos, and Pemba Island, Tanzania: a double-blin	153
Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the C	153
Long COVID: tackling a multifaceted condition requires a multidisciplinary approach	150
The importance of understanding the infectious microenvironment	147
Mpox in people with past infection or a complete vaccination course: a global case series	146
Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial	146
Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study	142
Post-viral sequelae of COVID-19 and influenza	141
Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention	137
History and evolution of tuberculosis and global health	137
Correction to Lancet Infect Dis 2023; published online Dec 15. https://doi.org/10.1016/S1473-3099(23)00744-2	137
Supporting healthcare access for refugees and migrants	137
Assessment of experimental malaria vaccine induced protection in pre-exposed populations	136
Election of Regional Director for the Western Pacific	136
The implications of mpox breakthrough infections on future vaccination strategies	134
High-dose primaquine reduces vivax relapses: time for change	133
Severe influenza: is there a role for antiviral combinations?	132
Sizing the reservoirs of malaria transmission: the contribution of school-aged children	132

Correction to Lancet Infect Dis 2021; 21: 962–74	131
CROI 2021	127
Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world	127
Emil Gotschlich	127
Interplay of infection and vaccination in long-term protection from COVID-19	126
Pre-emptively tackling vaccine misinformation for a successful large-scale roll-out of malaria vaccines in Africa	126
WHO Pathogen X conference	124
Immune evasiveness of SARS-CoV-2 variants and vaccine selection	123
Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis	122
Global cholera resurgence—a preventable tragedy	122
Studies of post-exposure prophylaxis with doxycycline should consider population-level selection for antimicrobial resistance	121
Assessing the burden of congenital rubella syndrome in China and evaluating mitigation strategies: a metapopulation modelling study	121
Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study	121
The global burden of cryptococcosis—a neglected tropical disease?	121
First data of a quabodepistat containing novel regimen for drug-susceptible tuberculosis	121
Factors associated with progression to death in patients with Lassa fever in Nigeria: an observational study	121
Super-spreaders: a historical review	119
Are we underestimating the annual risk of infection with Mycobacterium tuberculosis in high-burden settings?	118
Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-	118
Worrying lack of funding for tuberculosis	115
Elisabeth Presterl—always looking forward	114
Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis	114
Addressing the shortage of cholera vaccines	112
Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products—an update	111
Malaria vaccine development in Mali: a step towards transmission-blocking strategies	110
Knowledge gaps in the epidemiology of severe dengue impede vaccine evaluation	109
First immunogenicity data for the UK serogroup B meningococcal vaccination schedule in infants	109
Allergic bronchopulmonary aspergillosis with chest pain as atypical symptoms	107
Effect of change in vaccine schedule on pertussis epidemiology in France: a modelling and serological study	104
Correction to Lancet Infect Dis 2021; 21: 677–87	103
Correction to Lancet Infect Dis 2024; published online Feb 1. https://doi.org/10.1016/S1473-3099(23)00706-5	102
Correction to Lancet Infect Dis 2023; 23: e469	102
Correction to Lancet Infect Dis 2022; published online Aug 31. https://doi.org/10.1016/S1473-3099(22)00434-0	99
Correction to Lancet Infect Dis 2020; published online March 25. https://doi.org/10.1016/S1473-3099(21)00151-1	96
Correction to Lancet Infect Dis 2021; 21: 629–36	96
Research in brief	93
Full-dose NSAIDs at the first sign of respiratory infection?	91
Research in brief	90
Theresa Ochoa—staying on top of infectious diseases in Peru	89
The response of mpox-associated inflammatory syndrome to steroid therapy	89
Serpiginous-like choroiditis in ocular tuberculosis	89
We need estimates of gonorrhoea vaccine protection and symptomaticity by sex and anatomical site	87
Is combination antiviral therapy for influenza the optimal approach?	87
Infectious disease surveillance update	87
Tuberculosis recovery in Georgia: implementing more by 24	86
Linda-Gail Bekker—a leader at the service of the world	85
Curing chronic hepatitis B virus infection	84
Research in brief	84
Twin threats: climate change and zoonoses	84
The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant	84
BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents	84
Vaccine and surveillance implications of dengue underdetection	83
Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86	83
Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape	82
12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine	82
WHO's first global infection prevention and control report	82
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial	80
A decentralised point-of-care testing model to address inequities in the COVID-19 response	80
Guidelines adherence as a major protective aspect to increase survival rate in patients with candidaemia in Europe	80
Correction to Lancet Infect Dis 2025; 25: e47–58	78
An observer-blind, randomised, placebo-controlled, phase 1, single ascending dose study of dengue monoclonal antibody in healthy adults in Australia	78
Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study	78
Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis	77
Vaccine pragmatism in the 21st century	77
Human ocular thelaziosis—a zoonosis of the eye	77
Statistical concerns for meta-analysis of rare events and small sample sizes – Authors' reply	77
Detection of isoniazid, fluoroquinolone, ethionamide, amikacin, kanamycin, and capreomycin resistance by the Xpert MTB/XDR assay: a cross-sectional multicentre diagnostic accuracy study	77
Amal Saif Al-Maani—fighting antimicrobial resistance	76
Correction to Lancet Infect Dis 2021; 21: 929–38	75
Infectious disease surveillance update	75
Next-generation malaria subunit vaccines to reduce disease burden in African children	75
Outbreaks compound Brazil's flooding disaster	75
Community transmission of rotavirus infection in a vaccinated population in Blantyre, Malawi: a prospective household cohort study	74
Hong Kong's fifth COVID-19 wave—the worst yet	74
DoxyPEP: thinking towards implementation	73
Gender and geographical representation at infectious diseases and clinical microbiology conferences	73
A step closer to elimination of meningococcal disease	73
Spreading awareness on lymphatic filariasis	73
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial	73
Antifungal susceptibility testing: applicability of methods and strategies for improving access in resource-constrained settings	72

Child-friendly rifapentine formulation is a game changer	71
Incidence and risk factors of tuberculosis among 420 854 household contacts of patients with tuberculosis in the 100 Million Brazilian Cohort (2004–18): a cohort study	71
Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: a multicentre clinical study of two end-to-end commercial workflows	71
Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial	70
Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study	69
Lassa fever research priorities: towards effective medical countermeasures by the end of the decade	69
Community-based mpox and sexually transmitted disease surveillance using discarded condoms in the global south	69
Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3	68
Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis	68
The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study	67
Correction to Lancet Infect Dis 2024; published online Dec 17. https://doi.org/10.1016/S1473-3099(24)00588-7	67
Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study	67
Highlights from ECCMID 2022	66
RH5.1/Matrix-M: highlighting blood-stage malaria vaccines	66
Re-emergence of Oropouche virus in Brazil and Latin America	66
Ivermectin for malaria control in mass drug administration programmes	66
A tale of potential mpox reinfection	66
Cross-protective potential of a MF59-adjuvanted quadrivalent influenza vaccine in older adults	66
Advancing integration: progress reported for skin NTDs	66
Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer–BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study	66
Correction to Lancet Infect Dis 2023; published online Aug 3. https://doi.org/10.1016/S1473-3099(23)00344-4	65
Clindamycin-resistant Streptococcus pyogenes in Chinese children	65
The urgent need to scale-up fungal diagnostics in Africa	65
Correction to Lancet Infect Dis 2023; 23: e259–65	65
Sir Michael Anthony Epstein	64
Imprinted hybrid immunity against XBB reinfection	64
Sleeping sickness: time for dreaming	64
Prevention of non-ventilator-associated hospital-acquired pneumonia in Switzerland: a type 2 hybrid effectiveness–implementation trial	64
On the frontline during the COVID-19 pandemic	64
Is the end of gonorrhoea in sight?	64
Lessons learnt from conducting a randomised clinical trial in eumycetoma	63
Social workers and neglected tropical diseases	62
Pui-Ying Iroh Tam	62
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluste	62
doxyPEP: a controversial new tool against STIs	61
Eligibility of patients with Staphylococcus aureus bacteraemia for early oral switch	61
Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil	61
Research in brief	61
The origin of SARS-CoV-2 variants of concern	61
Effectiveness of pyriproxyfen-pyrethroid and chlorfenapyr-pyrethroid long-lasting insecticidal nets (LLINs) compared with pyrethroid-only LLINs for malaria control in the third year post-distribution:	61
Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices	60
Access to flucytosine for the treatment of HIV-associated cryptococcal meningitis in Africa	60
Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2	60
Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study	60
Re-emergence of Oropouche virus between 2023 and 2024 in Brazil: an observational epidemiological study	60
Moxidectin versus ivermectin for strongyloidiasis control	60
National case series of group A streptococcus pleural empyema in children: clinical and microbiological features	60
SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster	59
Lien Jih-ching	59
Experts react to SAGO's preliminary report	59
Detective doctor decodes AIDS mystery	59
Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial	59
What chikungunya teaches us about COVID-19	59
Monkeypox trial to begin in DR Congo	58
A new key-player for onchocerciasis elimination	58
Correction to Lancet Infect Dis 2021; 21: 677–87	58
Infectious disease surveillance update	58
Randomised controlled trials for mpox in endemic countries	57
Antibiotic stewardship in the real world	57
Correction to Lancet Infect Dis 2023; 23: 789	57
Navigating the storm of the 1980–90s AIDS epidemic	57
Antibody durability at 1 year after Sputnik V vaccination	57
Zika vaccines: can we solve one problem without creating another one?	56
Alexandra King—promoting Indigenous self-determination	56
A vanquished threat or a cautionary tale?	56
Understanding the immunogenicity of RTS,S in infants	55
Correction to Lancet Infect Dis 2025; 25: e11–12	55
Mpox control strategies: using behaviour change to complement, not replace, vaccination	55
Lessons from the English primary care sentinel network's response to the COVID-19 pandemic	55
Correction to Lancet Infect Dis 2021; published online Feb 1. https://doi.org/10.1016/S1473-3099(20)30738-6	55
Developing the EAVE III platform for future health crises	55
Correction to Lancet Infect Dis 2022; published online Jan 25. https://doi.org/10.1016/S1473-3099(21)00586-7	55
A shared history	54
Global measles cases up 20% in 2023	54
COVID-19 versus influenza: the need to align policies with COVID-19 realities	53
Antiblackness in the Ebola response in Sierra Leone	53
Transmissibility of SARS-CoV-2 among fully vaccinated individuals	52
A step forward for Plasmodium falciparum malaria transmission-blocking vaccines	52
Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1–4 cross-sectional survey results	52
Artificial intelligence to transform public health in Africa	51
Effect of single-dose, live, attenuated dengue vaccine in children with or without previous dengue on risk of subsequent, virologically confirmed dengue in Cebu, the Philippines: a longitudinal, prosp	51
Correction to Lancet Infect Dis 2024; published online Feb 9. https://doi.org/10.1016/S1473-3099(23)00731-4	51
Humanitarian crisis in Tigray amidst civil war	51
Impact of COVID-19 on migrants and refugees	50
Intention to vaccinate against COVID-19 in Australia	50
Deaths of unknown cause in DR Congo	50
Specificity and cross-reactivity of a test for anti-SARS-CoV-2 antibodies	50
The global alarm bell is ringing due to the threat of potential severe cases and deaths caused by clade I of monkeypox virus	50
Successful use of interferon alfa-2a for persistent parvovirus B19 infection	50
Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions	50
Disseminated Mycoplasma pneumoniae infection presenting with polyarthritis and endocarditis	50
H5N1 avian influenza: tracking outbreaks with real-time epidemiological data	49
Learning and confirming in publicly funded antiviral trials	49
Outbreak of sexually transmitted, extensively drug-resistant Shigella sonnei in the UK, 2021–22: a descriptive epidemiological study	49
A new formulation of praziquantel to achieve schistosomiasis elimination	49